Add To Watchlist
Share URL
About The Company
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases.
Read More
Overview
Value
1
Growth
2
Health
47
Management
11
Analyst Opinion
63
Total
25
All Scores Out Of 100
Best Features
- Earnings growth has improved recently
- Has a low level of debt
- Has a history of share buybacks
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- Income is not covering expenditure and investment
- Earnings are negative
- No margin of safety at their current market price
- Disliked by Twitter users
- Poor earnings and cashflow growth 0
Latest News
Wall Street Analysts Predict a 281.43% Upside in AlloVir, Inc. (ALVR): Here's What You Should Know
Zacks Investment Research | 16:18 Fri 10 Feb 2023
Read More →
AlloVir, Inc. (ALVR) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research | 18:32 Wed 25 Jan 2023
Read More →
How Much Upside is Left in AlloVir, Inc. (ALVR)? Wall Street Analysts Think 355.8%
Zacks Investment Research | 16:18 Wed 25 Jan 2023
Read More →
AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference
Business Wire | 12:00 Tue 3 Jan 2023
Read More →
Market Peers
ALVR
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
-1120.77%
Revenue Growth (5 Year Average)
N/A
Ratings Consensus
Neutral
Share Buybacks
14.85%
Dividend Yeild (TTM)
N/A
Valuation
Value Score
1
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: N/A✘
Current Price: 4.2 USD
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
-36.10%
PE/Earnings Growth
N/A
Price/Book
1.75x
Growth
Growth Score
2
- ✔ Revenue growth has improved this yeara
- ✔ Earnings growth has improved this year
- ✘ 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
- ✘ 5 Year Average Earnings growth of -24.83% is lower than the market average (14.48%)
- ✘ 5 Year Average Free Cashflow growth of -24.54% is lower than the market average (12.35%)
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
N/A
Earnings Growth
-24.83%
Cashflow Growth
-24.54%
Health
Health Score
47
Altman Z Score
N/A
Piostroski Score
N/A
Debt/Equity
0.16x
Current Assets/Liabilities
6.69x
Free Cashflow/Total Debt
N/Ax
Debt/Capital
0.14x
Management
Management Score
11
Average Buybacks/Dilution
14.85%
Recent Buybacks/Dilution
N/A
5 Year Price Volitility
30.78%
Return On Assets
-208.50%
Return On Capital Employed
-52.57%
Return On Equity
-265.26%
Return On Free Cashflow
978.83%
Return On Investments
N/A
Analysts
Analyst Opinion
63
- ✔ Ratings consensus is Neutral
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
AlloVir, Inc.
Currency
USD
Beta
0.667008
Vol Avg
270593
Ceo
Mr. David L. Hallal
Cik
0001754068
Cusip
019818103
Exchange
NASDAQ Global Select
Full Time Employees
107
Industry
Biotechnology
Sector
Healthcare
Ipo Date
2020-07-30
Address
139 Main Street
City
Cambridge
State
MA
Country
US
Zip
02451
Phone
617 433 2605
All financial data provided by FMP
Social Sentiment
Social Sentiment Score
29
Twitter Sentiment
N/A
Stocktwits Sentiment
57.00